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Abstract
Background: Endometrial cancer survivors comprise a high-risk group for obesity-related comorbidities. Healthy
eating and physical activity can lead to better health and well-being, but this population may experience difficulties
adopting healthy lifestyle practices. Personalised behaviour change programmes that are feasible, acceptable and
cost-effective are needed. The aim of this trial is to pilot a manualised programme about healthy eating and
physical activity.
Methods/design: This is a phase II, individually randomized, parallel, controlled, two-site, pilot clinical trial. Adult
endometrial cancer survivors (n = 64) who have been diagnosed with endometrial cancer within the previous
3 years and are not on active treatment will be invited to participate. Participants will be assigned in a 1:1 ratio
through minimisation to either an 8-week, group-based, behaviour-change programme with weekly 90-min
sessions about healthy eating and physical activity or usual care. The intervention will focus on self-monitoring,
goal setting and self-rewards. Follow-up assessments will be conducted at 8 and 24 weeks from the baseline
assessment. Primary feasibility outcomes will include rates of recruitment, adherence, and retention.
Discussion: The study results will inform the development of a definitive randomised controlled trial to test if the
programme can improve the health and quality of life of this population. It will also provide guidance on costing
the intervention and the health care resource use in this population.
Trial Registration: ClinicalTrials.gov identifier: NCT02433080, 20 April 2015.
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Background
Endometrial cancer is the most common gynaecological
cancer in developed countries, with more than 75 % of
the patients surviving for at least 5 years [1]. Low physical
activity, poor diet and obesity are risk factors for the
development of endometrial cancer [2]. These factors may
also be linked with quality of life after cancer treatment
[3]. While the evidence on the impact of post-diagnosis
health behaviours on endometrial cancer survival is still
unclear [4], evidence from other cancer sites suggests that
similar factors that affect cancer development may also
influence survival [5–8]. However, adherence to lifestyle
recommendations [9] is limited [10], putting survivors at
high risk for other chronic diseases.
Cancer survivors often report making health behaviour
changes [11]. As survivors might be motivated to
practice health-protecting behaviours, a cancer diagnosis
has been posited to be a ‘teachable moment’. However,
survivors rarely initiate lifestyle behavioural changes
[12–15]. Behaviour change interventions capitalising on
the ‘teachable moment’ might therefore be more effect-
ive than those targeting the general population [16, 17].
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While the optimal timing of the teachable moment has
not been defined, the post-treatment period seems opti-
mal for the provision of healthy eating interventions [18].
Promotion of physical activity might be independent of
timing [18], but 10 physical activity trials have accrued
survivors within a median of 3.1 years after their diagnosis
[19]. However, willingness to participate in health behav-
iour trials reduces with time since diagnosis in long-term
cancer survivors (>5 years since diagnosis) [20]. Qualita-
tive data in endometrial cancer survivors also support the
post-treatment period as the most appropriate time to
intervene [Koutoukidis et al: Attitudes, challenges, and
needs about diet and physical activity in endometrial can-
cer survivors: a qualitative study. Submitted]. While in a
vital position to do so, health professionals do not tend to
provide lifestyle advice [21], particularly given time con-
straints. Therefore, feasible and effective interventions are
needed to promote implementation of lifestyle
recommendations.
Rationale
Theory-based behaviour change interventions suggest
that improving diet and physical activity is safe, accept-
able and feasible with promising effects on both psycho-
logical and physiological outcomes, including quality of
life [22–25]. In the United States, the two interventions
in endometrial cancer survivors have also shown sus-
tained changes in behavioural outcomes and indicated
potential changes in quality of life domains [26—27].
Quality of life and its components are valuable outcome
measures, as they are associated with disease status and
the presence of co-morbidities, and they are core com-
ponents of strategic needs assessments for cancer survi-
vors [28]. However, the majority of these interventions
lasted for 6 months or more and were resource intensive
(for example, personalised materials, highly trained
coaches). Although cost-effective analyses are scarce
[29], such intensity or duration may render them in-
appropriate for wide dissemination. Furthermore, these
interventions may not be fully applicable to other cancer
groups given the differences between long-term treat-
ment effects. Qualitative work with endometrial cancer
survivors suggests they highly desire information regard-
ing specific late-treatment effects and advice on healthy
eating and physical activity post-treatment and in person
[Koutoukidis et al: Attitudes, challenges, and needs
about diet and physical activity in endometrial cancer
survivors: a qualitative study. Submitted]. Finally, simi-
larities in effectiveness of programs delivered across de-
veloped countries are expected. However, both the
health systems and the causes of obesity differ between
the USA and the United Kingdom [30]. Despite the
common focus of such programs on healthy eating and
physical activity, these differences might make a
program developed in one context less applicable in the
other.
A need exists, therefore, to develop effective behaviour
change interventions for endometrial cancer survivors
that meet an identified need and can be implemented in
the cancer care pathway both in terms of length of
programme and resource use. Pre-existing programmes
for improving diet and physical activity in the general
population, which have demonstrated usability within the
National Health Service (NHS), may be an untapped
resource. These programmes could be adapted to take
into account the specific needs and experiences of endo-
metrial cancer survivors while retaining the core compo-
nents that have made them effective in other populations.
Aim
The aim of this pilot study is to assess the feasibility of a
manualised healthy eating and physical activity programme
in endometrial cancer survivors post active treatment.
The main research question is as follows: ‘Is it feasible
to design a randomised controlled trial that will assess if
the Shape-up following cancer treatment programme is
more effective than usual care in improving the health-
related quality of life of endometrial cancer survivors?’
Study objectives
Primary research objective
The primary research objective is to assess the feasibility
of the overall trial procedures.
Secondary research objectives
Secondary research objectives are to accomplish the
following: (1) to obtain variance estimates for clinical out-
come measures to be used in the large-scale RCT that will
inform the measurement of the primary outcome for the
larger trial and, subsequently, the sample size calculation;
(2) to assess willingness of the clinical staff to recruit
participants; (3) to assess willingness of eligible partici-
pants to be randomised; (4) to examine potential adverse
effects of the intervention; (5) to perform a basic eco-
nomic analysis with the aim to inform the larger trial; (6)
to assess reasons for loss to follow-up; and (7) to access
the overall acceptability of the intervention.
Methods/design
The protocol has been prepared according to Standard
Protocol Items: Recommendations for Interventional
Trials (SPIRIT) [31] and Template for Intervention De-
scription and Replication (TIDieR) guidelines [32]. For
completed checklists, see Additional files 1 and 2.
Preliminary work
The intervention is based on Shape-up: a lifestyle
programme to manage your weight, an 8-week weight
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management programme, which aims to help service
users learn new behaviours and manage their weight
[33, 34]. This manualised healthy lifestyle programme
is based on social cognitive theory [35] and control theory
[36] and focuses on self-control, self-efficacy, and behav-
ioural relapse prevention. The intervention is under the
tier 2 weight management services [37] and in line with
NICE guidance on lifestyle weight management services
[17] and individual approaches in behaviour change [38].
Currently, a version of original program is successfully be-
ing run in two London boroughs as part of the local joint
strategic needs assessment [39].
The programme has been renamed (Shape-up follow-
ing cancer treatment: a self-help guide to eating well and
being active), and the intervention development process
will be separately reported. In brief, the tailored version
is focused on healthy eating and physical activity rather
than weight loss, a focus based on the lack of strong
evidence for the benefits of intentional weight loss in
cancer survival outcomes. A stronger focus on resist-
ance, flexibility and balance exercises has been be added,
given their benefits in cancer survivors [40, 41]. Further-
more, specific recommendations about radiotherapy and
chemotherapy treatment effects have been added to the
booklet, such as avoiding high-fat foods or choosing
cooked vegetables.
Study design
The DEUS pilot trial is an 8-week, two-arm, individually
randomised, controlled pilot trial comparing the use of
the Shape-up following cancer treatment programme to
usual care. According to MRC guidance for complex
interventions [42], this is a Phase 2 feasibility study.
Randomisation will be performed with minimisation,
using a 1:1 allocation.
Study setting
Participants will be recruited from two major academic
hospitals in London with sufficient caseload of endomet-
rial cancer patients; University College London Hospitals
NHS Foundation Trust, and Barts Health NHS Foun-
dation Trust. The intervention program will be deliv-
ered at the University College Hospital Macmillan
Cancer Support and Information Centre, located in
central London.
Selection of subjects
Inclusion criteria
Women aged > 18 years (no upper age limit) who
have been diagnosed with endometrial cancer (ICD
C54.1) within the previous 36 months will be eligible
to take part in the study. They must also be able to
understand spoken and written English. The cut-off
of 36 months was chosen to account for the duration
of treatment and allow for a sufficient pool of survi-
vors for recruitment, so the presence of the teachable
moment and the elimination of early major treatment
effects can be balanced.
Exclusion criteria
Women who meet at least one of the following
criteria will be excluded: (1) diagnosed with stage IVB
(metastatic) endometrial cancer (any metastasis be-
yond the pelvis); (2) undergoing active anticancer,
and/or palliative treatment; (3) having a second pri-
mary cancer; (4) lacking the mental capacity to decide
to take part in the study and to participate in it
(based on the clinical team’s judgement in accordance
with the Mental Capacity Act 2005 Code of Practice
2007); (5) having severe depression (consultant’s
judgement based on the DSM-IV criteria); (6) unavail-
able for longitudinal follow-up assessments; (7) having
participated in a professionally delivered weight loss
or exercise program during the previous 6 months;
(8) having a WHO performance score 3-4 [43]. These
criteria comply with all but the disability category in
the NICE Equality Impact Assessment for lifestyle
weight management services [17].
Interventions
Active intervention
A researcher in nutrition and dietetics (DAK), trained by
Weight Concern, who has clinical experience with can-
cer survivors, will facilitate the Shape-Up following
cancer treatment sessions following the standardised and
scripted manual. An extra trained provider will attend
the intervention meetings to aid with facilitation but will
not participate in the discussion. S/he will deliver the
intervention in case of unpredictable circumstances. In
addition to usual care, they will be assigned to groups of
eight on a first-come first-served basis to avoid delays in
delivering the intervention. These groups will meet for
weekly 90-minute sessions for 8 weeks.
The tailored version’s primary focus is on strategies for
improving healthy eating and physical activity and brief
advice on weight management for those who would like
it. Behavioural techniques include self-monitoring of be-
haviour with the use of food and physical activity diaries,
behavioural goal setting, action planning, graded tasks,
problem solving, self-reward, and review of behavioural
goals. It also provides information about the health
consequences and emotional consequences of making
dietary and activity changes, pros and cons, behavioural
practice, habit formation, reducing exposure to cues
for the behaviour, behaviour substitution, distraction,
social support (unspecified), demonstration of behav-
iour (for resistance exercises), instructions on how to
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Table 1 Structure and content of the Shape-up following cancer treatment sessions
# Session Session title Session content Approximate time
Session 1 Preparing to Shape-up Welcome and introduction to the programme 25 min
Setting ground rules for the group 10 min
Discussion about previous experience of diet and physical activity changes, how cancer
has shaped their eating and activity patterns, and hopes and fears about the programme
15 min
Motivation for change 10 min
Break 5 min
Setting a lifestyle target 10 min
Information and discussion about the importance of self-monitoring and food diaries 10 min
Round-up and preparation for next session 5 min
Take-home message 5 min
Session 2 Keeping to a regular
eating pattern
Review: Discussion about self-monitoring and food diaries and goal progress
Volunteer-led discussion: Keeping to a regular eating pattern
Key learning points: The importance of keeping to a regular eating pattern, the definition
of a regular eating pattern, the importance of breakfast, suggestions for goals, and
disadvantages of eating regularly.
New topic: Goals and rewards
Discussion about the principles of goal-setting, group exercise about setting SMART goals,
exercise about goal planning, discussion about rewards, and group exercise about
non-food rewards
Round-up and preparation for next session
Take-home message
Session 3 Physical activity Review: Discussion about keeping a diary, setting a regular eating goal, goal-setting,
rewards, and goal progress
20 min
Volunteer-led discussion: Physical activity 30 min
Key learning points: The importance of physical activity for health and wellbeing, the
difference between physical activity and exercise, goals to aim for (30 min of moderate
physical activity per day and muscle fitness exercises twice a week), and the importance
of incremental increase in physical activity levels.
Break 10 min
Setting an activity goal: individual exercise to help them focus on what they need to
think about in order to improve their activity levels and group exercise for improving
goal-setting skills
15 min
Round-up, and preparation for next session 10 min
Take-home message 5 min
Session 4 Eating a balanced diet Review: Discussion about last week’s topics and creating a physical activity goal
and goal progress
20 min
Volunteer-led discussion: Getting a healthier balance of foods. 30 min
Key learning points: the five food groups, choosing which foods to make (plenty of whole
grains, fruits, and vegetables; moderate amounts from the ‘meat, fish and alternatives’ and
‘milk and dairy’ groups, preferably low-fat; have little amounts of ‘foods high in fat or sugar’
and prefer healthy oils; limit processed meat, and sugary and alcoholic drinks; prefer
foods low in salt).
Break 5 min
New topic: Lapses 25 min
Information, group exercise, and discussion on how to deal with lapses
Round-up, and preparation for next session 5 min
Take-home message 5 min
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perform the behaviour (for resistance exercises), and
reframing [44].
The course structure and content are shown in Table 1.
The format of the intervention is self-help and peer edu-
cation. Each week, participants will be asked to read part
of the manual in preparation for the following week’s
new topic. Participants should set their first SMART goal
(Specific, Measureable, Attainable, Relevant, Time-bound)
for regular eating after the second session, and the first
SMART goal for physical activity after the third
Table 1 Structure and content of the Shape-up following cancer treatment sessions (Continued)
Session 5 Keeping an eye on food
serving sizes
Review: Discussion about last week’s topics, goal progress, and exercise about
managing lapses
20 min
Volunteer-led discussion: Keeping an eye on food serving sizes 50 min
Key learning points: Each participant brings a weighed portion of some foods, and
group members discuss understanding food serving sizes and how many servings
they should aim for (the food servings reflect a 2,000 kcal diet for women).
Break 10 min
Round-up and preparation for next session 5 min
Take-home message 5 min
Session 6 External triggers Review: Discussion about last week’s topics and goal progress 20 min
Volunteer-led discussion: External triggers 35 min
Key learning points: The difference between external and internal triggers, and main
strategies for dealing with external triggers
Break 5 min
New topic: Internal triggers 20 min
Discussion about hunger and cravings, group exercise for the dealing with cravings
and the difference between craving and hunger and discussion about fatigue
Round-up and preparation for next session 5 min
Take-home message 5 min
Session 7 Internal triggers Review: Discussion about last week’s topics, goal progress, and feelings about the
group coming to an end
20 min
Volunteer-led discussion: Internal triggers 40 min
Key learning points: Definition of internal triggers (hunger, cravings, fatigue, emotions,
and unhelpful thoughts) and strategies to deal with those
Break 5 min
New topic: Lapse chains 10 min
Information about lapse chains and group exercise of putting together a behaviour chain
Round-up, and preparation for next session 10 min
Take-home message 5 min
Session 8 Food labels and the
Shape-up change plan
Review: Discussion about last week’s topics and goal progress and reviewing earlier
areas of the programme
10 min
Volunteer-led discussion: Food labels 30 min
Key learning points: The ingredient list and the various names of sugar and saturated fat
in food labels, the importance of checking the sugar, saturated fat, and salt content in
the labels, and tips for smart shopping
Break 5 min
New topic: The Shape-up change plan 20 min
Information about how to complete a Shape-up change plan and individual exercise on
filling a mock plan
Discussion: Group members discuss their change plan, they re-evaluate their lifestyle
target from Session 1, and are given information about the importance of continuing
with self-monitoring
20 min
Round-up, and maintaining changes for the long term 5 min
Take-home message 5 min
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session. After each of the subsequent sessions, partici-
pants should set at least one eating and one physical
activity SMART goal.
Those who miss sessions will receive standardized e-mails
or mail with the content of the session. They will also be
asked not to discuss the intervention with fellow patients in
an attempt to minimize contamination and avoid leakage of
intervention details among patients in the study arms.
Control group
Participants in the control group will be offered usual
care. Quantifying usual care is challenging, but our pre-
liminary qualitative study suggested that lifestyle advice
is limited in the current clinical setting [Koutoukidis et
al Attitudes, challenges, and needs about diet and phys-
ical activity in endometrial cancer survivors: a qualitative
study. Submitted]. During the trial, participants will only
be contacted for the assessments. After the final follow-
up, the researcher will have a 5-minute discussion with
them using a standard statement focusing on the link be-
tween lifestyle and health consequences and targeting
their motivation to improve their health. At that point,
they will also receive the ‘Healthy living after cancer’
booklet, a brief self-help manual produced by the World
Cancer Research Fund [45].
Outcome measures
Primary outcome measures
The primary outcome measures for the pilot trial are as
follows:
1. The recruitment rate.
2. The adherence rate (attendance of the sessions).
3. The retention rate (complete follow-up).
The main criterion to judge the pilot study successful
and a large-scale RCT feasible using the recruitment
measure is recruiting (consenting) 30 % of the eligible par-
ticipants (32 participants per 110 estimated to be eligible
in each centre during the 6-month recruitment). This
target seems reasonable based on our previous experience
and similar rates indicated in the literature [46, 47]. The
primary measure to be used in the large-scale RCT is pro-
jected to be a change in global quality of life as measured
by the EORTC Quality of Life Questionnaire (QLQ-C-30).
However, the choice of additional primary outcomes will
be finalised after taking into account the results of the
feasibility study.
Secondary outcome measures
1. Clinical outcomes to be used in the large RCT
include the following:
I. Health-related quality of life
II. Diet quality
III. Physical activity
IV.Hand-grip strength
V. Weight
VI. Body composition
VII. Shape-up evaluation questionnaire
VIII.Healthcare services use
2. Willingness of clinical staff to recruit participants
will be assessed with a short one-to-one interview
with the clinicians at the beginning of the third
month of recruitment.
3. The number and type of potential adverse
effects of the intervention will be recorded
during the intervention and at the follow-up
interview (for example, gastro-intestinal
complaints from a change in diet).
4. Costs relevant to recruitment, screening,
implementation, and follow-up will be calculated.
We will also measure retrospectively the healthcare
resource use and cost them at national rates.
5. Reasons for non-participation and loss to follow-up
will be tracked for each participant lost and merged
in similar categories.
6. At 8 and 24 weeks follow-up, a purposive
sample (30 %) of participants in each arm will
be interviewed to assess their experience of
participating in the trial, the acceptability of the
intervention and the materials, and their overall
experience of the program, including potential
facilitators or barriers to adherence. All participants
who may dropout will also be approached for an
interview. These data will help with the refinement
of the intervention.
Participant timeline
Figure 1 demonstrates the flow chart of the study.
Table 2 shows the assessments at each time point.
Sample size
Although this is a feasibility study, a sample size has
been specified for examining the recruitment rate, using
A’Hern’s approach for one-stage phase II trials [48].
Regarding recruitment, a success rate of approximately
30 % or more would be desirable for the trial to be
considered feasible. A success rate of 15 % or less would
be unacceptable. The trial will test the null hypothesis
H0 that recruitment is ≤ 15 % against the alternative
hypothesis H1 that recruitment is ≥ 30 %. With a 5 %
level of significance and 90 % power, 64 participants
are needed so that we can estimate whether the per-
centage of participants with successful recruitment
is ≤ 15 % or ≥ 30 %. If we can recruit 15 or more
participants, we can reject the null hypothesis.
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A trial of 64 (32 per arm) will be sufficient to test the
above hypothesis and allow decisions to proceed to a
Phase III trial. It will also allow for rich feedback from
the participants to be used for the optimisation of the
procedures and the materials. Lastly, it will allow a
certain degree of precision in calculating standard devia-
tions for the secondary outcomes that will be the key
design parameters for the main study [49].
Recruitment
Potential participants will be recruited from outpatient
clinics at the two hospitals. They will be identified and
approached by a member of the clinical team. Bright
colour reminders will be attached at the cover of the
patient notes before their appointment to enhance
consultants’ engagement with recruitment. After initial
screening from the clinician, and if the patient is willing
to hear about the study, following verbal consent, the
patient will be introduced to the researcher attending the
clinic for final screening and a detailed discussion of the
study. All participants will need to consent for them-
selves following standard procedures (Additional file
3). We expect to recruit on average 1.07 participants
per week per hospital during the 30-week recruitment
period to reach our target.
The clinical teams in the two hospitals will also
identify potential participants who have been treated
in the two recruitment sites but have been followed
up at local sites. Following the General Practitioner’s
verification that the participants are alive, invitation
Fig. 1 Flow-chart
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letters signed by the consultant will be sent to these
women, along with the participant information sheet,
an opt-in form, the barriers to participation survey
[50], and a business reply envelope.
Assignment of interventions
Sequence generation
Consented participants will be individually rando-
mised with a 1:1 allocation to receive either the
intervention or usual care through minimisation
[51]. The two stratified variables are age (cut-off:
61 years) and obesity (BMI cut-off: 30 kg/m2), as
these are strong prognostic factors of all clinical
outcome measures. The age cut-off was chosen as
this is the median age of diagnosis for endometrial
cancer [52] and the BMI cut-off is the WHO cut-off
to classify obesity.
The allocated treatment will be determined using Mini-
mPY software run by RJB. Initially, the first participant will
be randomly allocated. For each of the following partici-
pants, allocation will be based on the imbalance scores,
calculated as a function of current allocations after a
hypothetical allocation of the new participant in each
study arm. The new participant will be allocated to the
arm with the least imbalance score [53]. A 20 % random
element will be included in the algorithm [51].
Allocation concealment mechanism
The researcher (RJB) who generates the allocation
sequence will keep the sequentially numbered opaque
sealed envelopes. The rest of the team will have no
physical access to them. The researcher will maintain
no contact with the rest of the group about the allo-
cation concealment until enough participants are
Table 2 Study assessments at specific time points
Study Period
Staff member Pre-study screening/consent Baseline Allocation Post-allocation
Time point Week -3 Week 0 Week 1 Week 8 Week 24
ENROLMENT
Eligibility screen Interviewer X
Informed consent Interviewer X
Allocation Study Coordinator X
INTERVENTIONS
Shape-up Interviewer
Usual care Interviewer
ASSESSMENTS
Socio-demographic data Interviewer X
EORTC-QLQ-C30 Interviewer X X X
EORTC-QLQ-EN34 Interviewer X X X
Dietary assessment Interviewer X X X
Physical activity Interviewer X X X
Weight Interviewer X X X
Height Interviewer X
Body composition Interviewer X X X
Waist circumference Interviewer X X X
Hand-grip strength Interviewer X X X
Blood pressure Interviewer X X X
Shape Up evaluation Interviewer X2 X2
Control group input Interviewer X3
Qualitative interviews Interviewer X X
Health care resource use Interviewer X
EQ5D-3 L Interviewer X X X
Serious adverse report form Study Coordinator As needed throughout the protocol
1Closeout for the control group will be at week 40 after receiving the intervention
2Only the intervention group
3Only in the control group
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allocated for a Shape-up following cancer treatment
group to run.
Implementation
Following the baseline assessment, DAK will feed back
to RJB the BMI and the age of the recruited participant
in a randomisation form in a sealed opaque envelope.
The latter will run the algorithm and allocate the
participant. This process will continue until enough
participants are allocated in both groups to run a
Shape-up following cancer treatment group. Apart from
RJB, all research team members will be blinded to
group allocation until a group can be run (for example,
the first 16 participants have been randomised). At that
point, participants will also be notified in which group
they have been allocated.
Blinding
Due to the nature of the intervention, neither partici-
pants nor the researchers delivering the intervention
can be blinded. The independent trained assessor for
the 8-week follow-up will be blinded to treatment
allocation, and requests have been made of the partic-
ipants not to disclose their allocation treatment. The
assessor of the 24-week follow-up (DAK) will not be
blinded given resource constraints.
Data collection, management and analysis
Data collection methods
Participants will visit the laboratory for three 90-min
one-to-one assessments. They will complete the widely
used, reliable and validated European Organization for
Research and Treatment of Cancer Quality of Life
Questionnaire (QLQ-C30) [54] and Endometrial Cancer
Module (QLQ-EN24) [55]. We will use the Stanford
7-Day Physical Activity Recall [56], a 15-min interview-
based tool, to assess physical activity, which has shown
acceptable reliability and validity [57] and is respon-
sive to change.
Dietary intake will be assessed with one weekday
24-hour dietary recall using the ASA24 web-based
tool [58]. Nutrition and statistical software will be
used to calculate how well the participant’s diet fits
to recommended healthy eating patterns. Our previ-
ous piloting of the assessment indicated acceptability
and feasibility. Diet quality will be calculated by the
Alternative Healthy Eating Index (AHEI) score, assessing
how well a diet fits to recommended healthy eating
patterns and being a strong predictor of survival [59]. An
updated version of the DINE questionnaire [60], together
with questions about fruits and vegetables, will supple-
ment the 24-hour dietary recall data.
Weight to the nearest 0.1 kg and body composition
will be assessed using MC980 multi-frequency segmental
body composition analyser. Using standardised proto-
cols, standing height will be assessed to the nearest
0.1 cm, and handgrip strength, using a handgrip dyna-
mometer. Waist circumference will be measured to the
nearest 0.1 cm [61]. Blood pressure will be measured
using an automated sphygmomanometer with the partici-
pant seated comfortably for 5 minutes before measure-
ment and the arm supported at the level of the heart. All
measurements will be taken twice and averaged for
analysis. Participants will also complete six socio-
demographic questions. Researchers will be receiving
standardised training with all measurements.
Participants will also complete the Shape-up question-
naire at all time points; ten items in a five-point Likert
scale (from ‘Strongly disagree’ to ‘Strongly agree’) that re-
flect the overall goals of the programme (for example, I
am in control of my food portion sizes, I can set effective
eating and activity goals and work towards them). At the
end of the program, the intervention-arm participants will
be given an 18-item evaluation form [62] to complete at
home and return by post. At the 24-week follow-up, the
control arm will complete two more questions assessing
the input about diet and physical activity they received
from external sources, to allow an assessment of contam-
ination. At the last follow-up, all participants will also
complete a healthcare resource using a six-item question-
naire [63]. Quality-of-life adjusted years (QALYs) will be
assessed with the validated six-item EQ5D-3 L [64].
After they have taken enough time to decide about
their participation, individuals will be asked their rea-
son(s) for non-participation [50]. The same questions
and prompts will be asked of participants who decide to
withdraw from the study. Participants may withdraw
from the study for any reason at any time. However, we
will make every reasonable effort to follow the partici-
pants for the entire study period. If a follow-up appoint-
ment in the laboratory is not possible after three
consecutive contact attempts, a researcher will request
to visit the participants at home for the interview or
undertake this by telephone. Participants will not be
aware of this option beforehand to maximise the
chances for having the physical measurements.
Data management
This study has been registered for Data Protection at UCL
Records Office (Reference: Z6364106/2014/12/14). Stand-
ard procedures following Data Protection Act 1998, the
NHS Code of Confidentiality, and Good Clinical Practice
will be implemented throughout the study.
Statistical methods
In addition to recruitment rate, the study is also examin-
ing adherence rate and retention rate (complete follow-
up). Adherence is defined as the proportion of engaged
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participants attending at least one of the last three
sessions of the intervention. Engaged participants are
those who have attended at least two sessions of the
intervention. Best practice guidance suggests that pro-
grammes should be commissioned if at least 60 % of
participants are likely to adhere [37]. A success rate
approximately of 85 % or more would be desirable.
That means that 85 % or more of the engaged partic-
ipants in the intervention group will attend at least
one of the last three sessions of the intervention. A
success rate of 60 % or less would be unacceptable.
The trial will test the null hypothesis H0 that adher-
ence is ≤ 60 % against the alternative hypothesis H1
that adherence is ≥ 85 %. With a 5 % level of signifi-
cance and 90 % power, 27 participants are needed so
that we can estimate whether the percentage of par-
ticipants with successful adherence is ≤ 60 % or ≥
85 %. If 21 or more participants have a successful ad-
herence, we can reject the null hypothesis.
Regarding retention (attendance of both follow-up
sessions) rate, a success rate of approximately 75 % or
more would be desirable. A success rate of 60 % or less
would be unacceptable. The trial will test the null
hypothesis H0 that complete follow-up is ≤ 60 % against
the alternative hypothesis H1 that complete follow-up
is ≥ 75 %. With a 5 % level of significance and 80 %
power, 62 participants are needed so that we can
estimate whether the percentage of participants with
complete follow-up is ≤ 60 % or ≥ 75 %. If 44 or more
participants have a complete follow-up, we can reject
the null hypothesis.
Recruitment, adherence and retention rates will be
reported as proportions with 95 % CIs. The target
lower 95 % confidence limit for the following out-
comes are 15 % or more, 60 % or more, and 60 % or
more for recruitment, adherence, and retention,
respectively.
Continuous variables will be reported by descriptive
statistics (non-missing sample size, mean, standard devi-
ation, median, maximum and minimum). Categorical
variables will be summarised using frequencies and per-
centages. Analysis of covariance (ANCOVA) will be used
to compare the intervention arm against the control arm
in an exploratory way, as the study is not powered to
detect differences. All participant data will be analysed
using the intention-to-treat strategy [65]. Adjustment for
BMI and age will be performed with linear regression in
continuous outcomes and logistic regression in binary
outcomes. Missing outcome data will be imputed using
multiple imputations. Reasons for missing data will be
documented, and missing data will be quantified. The
Statistical Package for Social Sciences (SPSS, Chicago,
IL) version 21 will be used for the whole data analysis.
Adverse events will be reported descriptively. The level
of statistical significance will be set at 5 % for the primary
outcome measures. We will also calculate intra-class cor-
relation coefficients (ICCs) to measure clustering within
groups and k coefficient of variation between groups.
Qualitative data will be analysed using thematic ana-
lysis. Two interview transcripts will be independently
coded by two researchers. These lists will be discussed
and amended between researchers upon agreement until
relevant themes are identified. DAK will insert the code
lists into NVivo software version 10 (QSR International
Pty Ltd, 2014). NVivo version 10 (QSR International Pty
Ltd, 2014). Two random transcripts will be recoded by
an independent researcher to ensure consistency.
Monitoring
Data monitoring
Given the short length of the intervention, the low risk
of harm (see below) and the short follow-up of the
intervention, an external Data Monitoring Com-
mittee will not be needed and an interim analysis
will not be performed. Nonetheless, the researchers
recruiting, implementing, and assessing the interven-
tion will update the research team monthly about
the study progress.
Harms
Shape-up following cancer treatment is a very low inten-
sity intervention that should be suitable for most people
with health conditions, such as diabetes, heart failure,
and high blood pressure. Observed changes are unlikely
to be associated with unintended or adverse effects [17].
The proposed modifications to lifestyle, that is, dietary
and physical activity changes, are in accordance with
published guidelines for cancer survivors [9]. All potential
adverse effects and unintended effects of the intervention
will be reported.
Auditing
The sessions will be audiotaped and the recording
will be coded against the Shape-up following cancer
treatment Facilitators manual for assessing interven-
tion delivery and treatment receipt by a researcher
experienced in health psychology and behaviour
change [66]. The group facilitator (DAK) will also
audio record a short debriefing after each session.
RJB will randomly perform undisclosed site visits in
two assessments and one intervention session to as-
sess protocol fidelity. The Shape-up evaluation form,
which includes a self-assessment of the gained skills
and an evaluation of the facilitator, will supplement
fidelity assessment. Results will inform improvements
in protocol fidelity.
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Ethics and dissemination
Research ethics approval
The study protocol and documents have been reviewed
and approved by the relevant sponsor and National
Research Ethics Service Committee London - City Road
and Hampstead (Reference: 15/LO/0154).
Protocol amendments
Potential protocol modifications will be formally approved
by the REC before being implemented. The amendments
will be communicated to the trial registries and outlined
at the study dissemination.
Post-trial care
Archiving
Study-related documents will be archived at UCL
and each participating site at the end of the study
for 20 years and in line with all relevant legal and
statutory requirements.
Dissemination policy
The period for study dissemination will be kept to
the minimum possible. The primary papers will report
the primary outcome measures. The results will be
disseminated regardless of the magnitude or direction
of effect. All investigators will be authors of future
publications with authorship eligibility to follow inter-
national guidelines [67]. The study results will also be
disseminated to the clinical teams in the participating
centres and to the participants. A completely de-
identified dataset will be disseminated to a relevant
data archive for sharing purposes no later than 3 years
after the study closeout.
Roles and responsibilities
Trial Management Group
DAK will be responsible for the daily monitoring and
management, reporting directly to AL. AL has overall
responsibility for the project. The two study site CIs
(AL, RM) will oversee the identification of potential
participants. RJB and TMK will provide expert advice
during the study and the analysis and interpretation of
the results. Professor Steve Morris will provide advice
regarding the health economic aspects. RJB will be re-
sponsible for the intervention assignment and auditing.
Trial Steering Committee
An external Trial Steering Committee that will meet at
regular intervals during the study will oversee the trial.
The committee, which is chaired by Professor Allan
Hackshaw, will include two other independent members,
the two site PIs (AL and RM), the trial co-investigators
and a lay representative.
Discussion
In the UK, only a few studies have demonstrated the
feasibility of interventions for lifestyle behaviour change
in cancer survivors [68, 69]. None of them, however, has
involved the growing population of endometrial cancer
survivors. This feasibility trial will inform a larger life-
style trial in cancer survivors to test if the program can
help survivors to improve their quality of life. The
outcome of this pilot study will be translated as (a) a
feasible study that should be continued without modifi-
cations, (b) a feasible study with close monitoring that
should be continued without modifications, (c) a feasible
study with modifications in the protocol or (d) a non-
feasible study. The study has the potential not only to
help cancer survivors improve their well-being but also to
help NHS reduce its cost by potential reduction of the use
of its services as survivors will lead a healthier lifestyle.
The current intervention is in accordance with the
National Cancer Survivorship Initiative, which envisages
a sustainable personalised lifestyle support for cancer
survivors with them playing an active part in the
decision-making in addition to research on patient-
reported outcomes [70]. If proven effective, we hope that
Shape-up following cancer treatment will be dissemi-
nated nationally as a low-cost, self-help, group program.
The manualised format and the facilitator’s guide allow
for standardised training for facilitators that could be
non-healthcare professionals, accurate replication and
evaluation across settings.
Trial status
The trial is currently recruiting participants.
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